Not an HIV cure, but encouraging new directions

New England Journal of Medicine

Volumn 360, Issue 7, 2009, Pages 724-725

  Levy, Jay A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; SMALL INTERFERING RNA; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; DRUG COST; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PRIORITY JOURNAL; CD4 LYMPHOCYTE COUNT; DRUG ANTAGONISM; GENE THERAPY; NOTE; STEM CELL TRANSPLANTATION;

ANTIGENS, CD4; CD4 LYMPHOCYTE COUNT; GENE THERAPY; HIV; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; STEM CELL TRANSPLANTATION;

EID: 60549095623     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0810248     Document Type: Editorial

References (15)

1. Prescott WH. History of the conquest of Mexico and the history of the conquest of Peru. New York: Rowan & Littlefield, 2000.
2. Levy JA. HIV and the pathogenesis of AIDS. 3rd ed. Washington, DC: ASM Press, 2007.
3. Shearer GM, Clerici M. Protective immunity against HIV infection: has nature done the experiment for us? Immunol Today 1996;17:21-4.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
5. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;127:882-90.
6. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
7. Jubault V, Burgard M, Le Corfec E, Costagliola D, Rouzioux C, Viard J-P. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. AIDS 1998;12:2358-9.
8. Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005;4:201-18.
9. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8.
10. Cohen J. Building an HIV-proof immune system. Science 2007;317:612-4.
11. An DS, Donahue RE, Kamata M, et al. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci U S A 2007;104:13110-5.
12. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004;15:290-9.
13. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol 2001;22:312-6.
14. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006;203:35-40.
15. Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet 2006;367:711-3.